Will BMS's 'Revlimid' be reimbursed as RVd therapy?

By Eo, Yun-Ho | translator Alice Kang

21.11.10 16:48:10

가나다라 0

Expectations rise with PBAC review of the agenda… focus in on whether an alternative for elderly patients will finally be introduced to the field

RVd therapy improved PFS compared to Rd therapy in a Phase III trial

Whether the multiple myeloma treatment ‘Revlimid’ will succeed in expanding reimbursement to its use in RVd therapy is gaining attention.

According to industry sources, reimbursement of Revlimid (lenalidomide) for RVd therapy (Lenalidomide + bortezomib + dexamethasone) passed the Health Insurance Review and Assessment Services’ Cancer Disease Deliberation Committee review in September and is awaiting deliberation by the Pharmaceutical Benefits Appraisal Committee. The agenda is expected to be presented for PBAC deliberation in December.

In Korea, the standard first-line therapy for multiple myeloma under reimbursement includes VMP (bortezomib+ melphalan+ prednisolone) and Rd (lenalido

Eo, Yun-Ho(unkindfish@dailypharm.com)

If you want to see the full article, please JOIN US (click)